ClinicalTrials.gg
Active, not recruitingNCT04641819Updated May 31, 2024

Yangzheng Compound Mixture in the Treatment of Sleep Disorder in Cancer Patients

A Phase 4 interventional study of Yangzheng Compound Mixture and Conventional Treatment in Carcinoma and Sleep Disorder, sponsored by ShuGuang Hospital. Active, not recruiting at 10 sites in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-05-31.

Sponsored by ShuGuang Hospital · Phase 4, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
1,127
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 101 studies in Carcinoma with a site in China — 37 open to participants now, 49 under way, 12 of them phase 3. Carcinoma · China.

Enrollment
2nd of 82
1,127 · median 72
Started
2021
with 9 others
Phase 4
4 of 101
1 open now
Primary completion
2023-09
later than 3 of 48 live
Registered
50th of 101
by date

Among the 101 studies in Carcinoma with a site in China, this one is the 2nd largest by enrollment of the 82 interventional ones that give a count, is one of 10 that started in 2021, is one of 4 in phase 4, reaches primary completion later than 3 of the 48 other live ones, and was the 50th registered.

Carcinoma

736 studies on the registry are indexed under Carcinoma; 149 are open to participants now.

Browse Carcinoma studies →

Open to participants now

37 of the 101 studies in Carcinoma with a site in China are open now. Recruiting first, the newest first:

32 more — sign in →

All 37 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 115 Carcinoma studies recruiting now, 92 (80%) set no upper age limit and 14 (12%) stop at 75 or younger; 11 take children under 18; 4 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 101 studies in Carcinoma with a site in China, or all of them as a file.
02

Study summary

This is a nationwide, multicenter, randomized, prospective, real-world study. The purpose of this study is to evaluate the effect and safety of Yangzheng Compound Mixture in the treatment of sleep disorder in cancer patients with Qi-Yin deficiency syndrome during chemotherapy.

Read the detailed description

Sleep disturbance is one of the most common symptoms in cancer patients, the morbidity is about 60%. Drugs commonly used to treat sleep disorders include benzodiazepines, hypnotic antidepressants and melatonin receptors agonists. The short-term efficacy of these drugs has been proven in many clinical trials, but long-term medications bear the risk of adverse reactions and addiction.

Yangzheng Compound Mixture is an extract of several traditional Chinese medicines, used as a basic prescription for cancer therapy, especially for patients who received chemotherapy with Qi-Yin deficiency syndrome, which often lead to sleep disturbance, fatigue and anorexia. According to some clinical and basic studies, Yangzheng Compound Mixture also has antitumor and immunomodulatory effects.

In this study, about 10 research centers will participate. We planned to enroll 1526 cancer patients (1144 cases in the observation group and 382 cases in the control group) with Qi-Yin deficiency Syndrome and sleep disorders during the period of receiving chemotherapy or combination of chemotherapy. The dynamic random method was adopted in this study, participants will be randomly divided into the experimental group (Yangzheng Compound Mixture plus conventional treatment) and control group (conventional treatment only), all of them will be interviewed once every 3 weeks until the end of the study.

03

Conditions studied

  • Carcinoma
  • Sleep Disorder

Keywords

  • Yangzheng Compound Mixture
  • Carcinoma
  • Sleep Disorder
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age ≥18;
  • or cytologically confirmed as malignant tumor;
  • Receiving chemotherapy or a combination of chemotherapy;
  • The syndrome differentiation of traditional Chinese medicine is the Qi-yin deficiency syndrome;
  • Sleep disorders were diagnosed by investigators and the Pittsburgh Sleep Quality Index (PSQI) score was ≥ 8;
  • The date of diagnosis of sleep disorder is later than the date of the first diagnosis of cancer. Or patients with sleep disorders for a long time receiving regular treatment,sleep disorders aggravated after cancer diagnosis or chemotherapy;
  • Pain has been controlled well [patients were being treated with analgesics regularly,numerical rating scale(NRS) score ≤ 3];
  • The participant must be able to read and express themselves clearly, can communicate with investigators and cooperate in completing the questionnaire;
  • Participants voluntarily join the study with good compliance, and are willing to sign a written document;
  • Survival period will be longer than 6 months.

Exclusion criteria

Exclusion Criteria:

  • Pregnant or lactating women;
  • Allergic to Yangzheng Compound Mixture;
  • Previous diagnosis of sleep apnea;
  • The laboratory test value of liver and renal function is more than 2.5 times the value;
  • Symptoms of due to malignant tumor has not been effectively controlled;
  • Participating in other drug clinical trials which did not allow to participate in this study;
  • Refused to cooperate with follow-up;
  • The researchers did not consider it appropriate for the patients to participate in this study for other reasons.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
1,127 participants (actual)

Study arms

  • Experimental
    Yangzheng Compound Mixture plus conventional treatment

    Yangzheng Compound Mixture: 10mL, 2 doses each time, 3 times a day, three weeks for a course of treatment. Investigators recommended that the participants of experimental group should use Yangzheng Compound Mixture for 2 courses at least. Conventional treatment: Antitumor therapies: chemotherapy or combined chemotherapy. Sleep disorders: includes but is not limited to pharmacotherapy and exercise therapy. The examination, diagnosis and treatment of other concomitant diseases and tumor complications are based on clinical routine. We will collect information about all the combined medicine.

    Drug: Yangzheng Compound Mixture · Other: Conventional Treatment

  • Other
    conventional treatment only

    Antitumor therapies: chemotherapy or combined chemotherapy. Sleep disorders: includes but is not limited to pharmacotherapy and exercise therapy. The examination, diagnosis and treatment of other concomitant diseases and tumor complications are based on clinical routine. We will collect information about all the combined medicine.

    Other: Conventional Treatment

Interventions

  • DrugYangzheng Compound Mixture

    At the end of the treatment period, the investigator can decide whether to continue the medication based on the improvement of the subjects' sleep disturbance. Medication during the follow-up period: subjects will enter the follow-up period after completing one course of Yangzheng Compound Mixture treatment or the end of the treatment period. Visits will be conducted once every 3 weeks, at least 2 times and no more than 4 times. For subjects in the experimental group, doctors can decide whether the patients should continue to receive Yangzheng Compound Mixture therapy in the follow-up period according to the improvement of sleep disorders, while for subjects in the control group, the patients can choose to start receiving Yangzheng Compound Mixture therapy in the follow-up period according to their own wishes and doctors' suggestions.

    Also known as: Z10970042(NMPA Approval Number)

  • OtherConventional Treatment

    Including treatment of sleep disorders and tumor which shall follow the clinical guidelines.

06

What researchers measure

Primary outcomes

  1. Best effective rate for sleep disorder treatment

    Proportion of participants with a minimum PSQI score \< 8 during the treatment period.

    Time frame: Measurement was taken at week 6.

  2. Effective rate for sleep disorder treatment

    Proportion of participants with PSQI score \< 8 after the end of the different treatment courses.

    Time frame: Measurement was taken at week 6.

  3. Improvement rate for sleep disorder treatment

    Proportion of participates whose PSQI score decreased during treatment compared with the baseline.

    Time frame: Measurement was taken at week 6.

  4. Change of PSQI score compared with baseline

    The PSQI score difference between the end of different treatment courses and baseline.

    Time frame: Baseline and week 6.

  5. Score of Pittsburgh Sleep Quality Index (PSQI), Sleep duration, Sleep efficiency, Subjective sleep quality, Sleep latency.

    1. The outcomes were evaluated using the PSQI scale. 2. Sleep duration: response to question 4; 3. Sleep efficiency= (hours slept/ hours in bed) \* 100%; Hours slept: response to question 4; Hours in bed: calculated from responses to questions 1 and 3; 4. Subjective sleep quality: response to question 9; 5. Sleep latency: response to question 2.

    Time frame: Measurement was taken at week 6.

  6. Incidence and severity of AE or SAE

    AE: Any untoward medical occurrence in a patient or clinical investigation subject administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment. SAE: A serious adverse event (experience) or reaction is any untoward medical occurrence that at any dose: results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, or is a congenital anomaly/birth defect.

    Time frame: Start of treatment until 30 days after the last day of the sleep disorder treatment

  7. Incidence and severity of ADR or SADR

    All noxious and unintended responses to a medicinal product related to any dose should be considered adverse drug reactions. A SADR is a serious ADR according to the above criteria of SAE.

    Time frame: Start of treatment until 30 days after the last day of the sleep disorder treatment

Secondary outcomes

  1. Use frequency of hypnotic agents

    Response to question 6 of the PSQI scale.

    Time frame: Up to 18 weeks since the start of treatment

  2. Appetite

    Appetite was evaluated by using the Cancer Appetite and Symptom Questionnaire(CASQ).

    Time frame: Up to 18 weeks since the start of treatment

  3. Fatigue

    Fatigue was evaluated by using the Brief Fatigue Inventory(BFI).

    Time frame: Up to 18 weeks since the start of treatment

  4. Quality of life (QOL)

    Quality of Life (QOL) was measured by using the European Organization for Research and Treatment of Cancer Core Quality of Life Questionnaire (EORTC QLQ-C30).

    Time frame: Up to 18 weeks since the start of treatment

  5. Traditional Chinese Medical symptoms scale

    Traditional Chinese Medical (TCM) symptoms were measured from these six aspects: weakness, shortness of breath, palpitations, deficiency-heat and vexation, dry mouth, sweat. The minimum score is 0 and the maximum value is 18. Higher scores of TCM scale means a worse outcome.

    Time frame: Up to 18 weeks since the start of treatment

Other outcomes

  1. Proportion of leukocyte-increasing drugs used

    Proportion of participates used leukocyte-increasing medication during the treatment period

    Time frame: Up to 18 weeks since the start of treatment

07

Study locations

10 sites
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Apr 2021 to primary completion in Sep 2023, 29 months.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 6, 2020
First posted
Nov 24, 2020
StartActual
Apr 27, 2021
Primary completionActual
Sep 30, 2023
CompletionEst.
Jun 30, 2024
Last update
May 31, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 31, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04641819
Lead sponsor
ShuGuang Hospital
Collaborators
LinkDoc Technology (Beijing) Co. Ltd., Shaanxi Buchang Pharmaceutical Co., Ltd
Responsible party
Qi Li (Professor, ShuGuang Hospital) — Principal investigator
First posted
Nov 24, 2020
Start date
Apr 27, 2021
Primary completion
Sep 30, 2023
Completion
Jun 30, 2024 (estimated)
Last update
May 31, 2024

Study contacts

Qi Li, PhD
principal investigator · Shuguang Hospital Affiliated with Shanghai University of TCM

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in May 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion